Sermonix Pharmaceuticals to Present Three Posters Focused on Precision Medicine in the Treatment of Metastatic Breast Cancer ...
November 14 2018 - 10:00AM
Posters to be displayed at Dec. 4-8 conference address
introduction of Phase 2 study of investigational drug lasofoxifene,
its effect on breast cancer and lung and liver metastasis in an in
vivo model, and oncologists’ perceptions of ESR1 mutations and
biomarker testing.
Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical
company focused on the development and commercialization of
female-specific oncology products, today announced the acceptance
of three posters for presentation at the 2018 San Antonio Breast
Cancer Symposium (SABCS). The accepted presentations demonstrate
Sermonix’s continued momentum toward realizing the potential of its
lead investigational drug, lasofoxifene, as an oral targeted
treatment for women with ESR1 mutations in metastatic breast
cancer.
The Dec. 4-8 meeting at the Henry B. Gonzalez Convention Center
in San Antonio will include the following posters:
- An open-label, randomized, multi-center Phase 2 study
evaluating the activity of lasofoxifene relative to fulvestrant for
the treatment of postmenopausal women with locally advanced or
metastatic ER+/HER2 - breast cancer (MBC) with an ESR1
mutation ° Presenting author Matthew Goetz,
M.D., Mayo Clinic ° Poster Session OT (OT1-01-02);
Wed., Dec. 5, 5pm-7pm
- A preliminary assessment of knowledge, attitudes, and
awareness surrounding ESR1 mutations and biomarker testing amongst
medical oncologists ° Presenting author
Shari Goldfarb, M.D., Memorial Sloan Kettering Cancer Center
° Poster Session 5 (PD5-11-11); Fri. Dec. 7,
5pm-7pm
Spotlight Session
- Lasofoxifene decreases breast cancer lung and liver
metastasis in a mammary intraductal (MIND) xenograft model of
mutant ER-alpha+ breast cancer
° Presenting author Muriel Lainé, Ph.D., University of
Chicago ° Poster Session 7 (PD7-09); Fri., Dec. 7,
7am-9am
One poster introduces a Phase 2 trial of oral lasofoxifene,
evaluating its activity versus intramuscular fulvestrant for the
treatment of postmenopausal women who have locally advanced or
metastatic estrogen receptor-positive (ER+)/HER2- breast cancer
with an ESR1 (estrogen receptor gene) mutation. Another poster,
selected for a spotlight session on endocrine resistance, is
Sermonix-sponsored research from the University of Chicago Ben May
Department for Cancer Research in a MIND xenograft model of mutant
ER+ breast cancer. The third poster will share results of a study
on medical oncologists’ knowledge, awareness and perceptions of
precision medicine and liquid biopsy biomarker testing specific to
breast cancer and ESR1 mutations.
“Lasofoxifene’s potency and newly discovered activity in ESR1
mutations may hold promise for patients who have acquired
resistance in an area of significant unmet medical need,” said
David Portman, M.D., Sermonix founder and chief executive officer.
“We look forward to presenting exciting data at this year’s San
Antonio Breast Cancer Symposium as we move lasofoxifene forward as
a targeted therapy for women with advanced breast cancer.”
“Clinical data have shown a significant reduction in the
incidence of ER+ breast cancer in postmenopausal women with
osteoporosis who were treated with lasofoxifene,” said Paul
Plourde, M.D., Sermonix vice president of clinical development.
“Further non-clinical and clinical study results provide a strong
rationale for pursuing a Phase 2 clinical trial comparing
lasofoxifene to fulvestrant, a current widely used injectable
medication for advanced breast cancer.”
“Lasofoxifene’s ability to reduce primary tumor weights and
inhibit metastasis of ER-mutated breast cancer xenografts in a
mouse mammary intraductal (MIND) model was reported at the Annual
Meeting of the American Society of Clinical Oncology in June this
year,” said Geoffrey Greene, Ph.D., chair of the Ben May Department
for Cancer Research and co-director of the Ludwig Center for
Metastasis Research at the University of Chicago. “We look forward
to sharing new data on lasofoxifene’s impact on lung and liver
metastases in breast cancer xenografts that express mutant ER.”
Muriel Lainé, a senior research professional in Greene’s lab,
will serve as presenting author for the Spotlight Session in San
Antonio.
About LasofoxifeneLasofoxifene is an
investigational, nonsteroidal selective estrogen receptor modulator
(SERM), which Sermonix licensed from Ligand Pharmaceuticals Inc.
(NASDAQ: LGND) and has been studied in previous comprehensive Phase
1-3 non-oncology clinical trials in more than 15,000 women
worldwide.
Lasofoxifene’s binding affinity and activity in mutations of the
estrogen receptor could potentially hold promise for patients who
have acquired endocrine resistance and ESR1 mutations, a common
mutation in the metastatic setting and an area of high unmet
medical need. Lasofoxifene’s novel activity in ESR1 mutations was
recently discovered and Sermonix has exclusive rights to develop
and commercialize it in this area. A potent, well-characterized and
bioavailable SERM, lasofoxifene, if approved, could play a critical
role in the personalized treatment of advanced ER+ breast
cancer.
About SermonixSermonix Pharmaceuticals LLC is a
biopharmaceutical company with a targeted focus on bringing
female-specific oncology products through proof of concept,
preclinical and clinical development, and regulatory approval. The
company was founded in 2014 by David Portman, M.D., a leading
clinical researcher and expert in women’s health, menopause and
selective estrogen receptor modulator (SERM) therapy. Sermonix has
as its lead product oral lasofoxifene. The Sermonix management
team, led by Dr. Portman, has significant experience in all stages
of the drug development and regulatory process. Paul Plourde, M.D.,
vice president of oncology clinical development, was previously
with Astra-Zeneca, where he was instrumental in the development and
approval of tamoxifen, Arimidex® and Faslodex®. Barry Komm, Ph.D.,
chief scientific officer, was former head of the SERM program at
Wyeth and Pfizer, playing a key role in the development and
approval of bazedoxifene and Duavee®. Elizabeth Attias, M.M.Sc.,
Sc.D., vice president of business development, has extensive
experience in pharmaceutical drug commercialization. Sermonix
non-executive chairman of the board is Anthony Wild, Ph.D., former
president of both Parke-Davis Pharmaceuticals and Warner-Lambert’s
Pharmaceutical Division. Learn more at
http://sermonixpharma.com/
Contact:David Portman, MDCEO and Founder, Sermonix
Pharmaceuticalsdportman@sermonixpharma.com614-582-6849
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ligand Pharmaceuticals (NASDAQ:LGND)
Historical Stock Chart
From Apr 2023 to Apr 2024